Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Merestinib Monotherapy or in Combination With Cisplatin and Gemcitabine in Japanese Patients With Advanced and/or Metastatic Cancer
jRCT2080223458Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of merestinib in Nonhematologic neoplasms, non-Hodgkin lymphoma (NHL) and biliary cancer (2 arms), sponsored by Eli Lilly and Company. Started Feb 2017; status: completed.
02
Drugs
merestinib
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)biliary cancer
Beyond the preview
Go deeper on jRCT2080223458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223458.